Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Olinvacimab (TTAC-0001), a fully human anti-VEGFR2 monoclonal antibody, demonstrates antiangiogenic activity by inhibiting VEGF binding to KDR, with a dissociation constant (K d) of 0.23 nM. It is utilized in research for treating recurrent glioblastoma and breast cancer [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Olinvacimab (TTAC-0001), a fully human anti-VEGFR2 monoclonal antibody, demonstrates antiangiogenic activity by inhibiting VEGF binding to KDR, with a dissociation constant (K d) of 0.23 nM. It is utilized in research for treating recurrent glioblastoma and breast cancer [1]. |
Molecular Weight | N/A |
CAS No. | 2095504-49-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Olinvacimab 2095504-49-5 inhibitor inhibit